Tejara Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Tejara Capital’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-68,757	Closed	-$892K	–	86
2023 Q4	$892K	Sell	68,757 -3,069	-4%	-$41.4K	0.37%	49
2023 Q3	$1.44M	Sell	71,826 -4,440	-6%	-$99.6K	0.82%	34
2023 Q2	$2.05M	Buy	76,266 +42,829	+128%	+$1.84M	1.01%	29
2023 Q1	$1.95M	Hold	33,437	–	–	1%	32
2022 Q4	$1.71M	Buy	+33,437	New	+$2.32M	0.98%	31

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tejara Capital's KPTI Position: Q1 2024 in Review

Tejara Capital sold out of Karyopharm Therapeutics (KPTI) in Q1 2024, closing a stake of 68,757 shares — an estimated $892K sold.

Tejara Capital first reported a position in KPTI in Q4 2022 and held it in 5 quarters. The position peaked at $2.05M in Q2 2023. 113 funds tracked by Wall St. Rank hold KPTI as of Q1 2024.

Tejara Capital reported no remaining Karyopharm Therapeutics position as of Q1 2024 after selling out during the quarter.
Tejara Capital sold 68,757 Karyopharm Therapeutics shares in Q1 2024, an estimated $892K.
Tejara Capital first reported a position in Karyopharm Therapeutics in Q4 2022 and held it in 5 quarters.
Tejara Capital's Karyopharm Therapeutics position peaked at $2.05M in Q2 2023.
113 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2024.

Based on Tejara Capital's 13F filing for Q1 2024, filed 14 May 2024.